b
r
c
respiratori
tract
infect
selflimit
caus
virus
warrant
antibiot
treatment
despit
patient
respiratori
tract
infect
often
receiv
antibiot
fuell
rise
antibiot
resist
therefor
need
encourag
patient
tri
altern
nonantibiot
therapi
ideal
treat
symptom
caus
lozeng
contain
amylmetacresol
alcohol
amcdcba
lozeng
well
lozeng
contain
hexylresorcinol
shown
provid
effect
symptomat
relief
sore
throat
studi
investig
whether
lozeng
also
virucid
effect
vitro
two
virus
associ
respiratori
tract
infect
parainfluenza
viru
type
cytomegaloviru
virus
incub
amcdcba
lozeng
placebo
lozeng
activ
ingredi
amcdcba
free
substanc
parainfluenza
viru
type
incub
hexylresorcinol
lozeng
placebo
lozeng
hexylresorcinol
free
substanc
virucid
effect
observ
activ
lozeng
activ
ingredi
free
substanc
parainfluenza
viru
type
cytomegaloviru
mean
reduct
viral
titr
significantli
greater
compar
placebo
lozeng
peak
effect
observ
shortest
incub
time
min
find
suggest
amcdcba
lozeng
hexylresorcinol
lozeng
potenti
local
antivir
effect
patient
sore
throat
due
viral
respiratori
tract
infect
use
overthecount
treatment
selflimit
respiratori
tract
infect
may
satisfi
patient
desir
antiinfect
medic
reduc
demand
antibiot
respiratori
tract
infect
rti
common
ill
affect
human
denni
typic
symptom
includ
sore
throat
rhiniti
cough
fever
dasaraju
liu
eccl
rti
caus
viral
infect
denni
exampl
symptom
sore
throat
report
caus
virus
case
adult
children
year
children
age
year
worral
virus
associ
rti
includ
orthomyxovirus
influenza
paramyxovirus
parainfluenza
virus
piv
respiratori
syncyti
viru
rsv
coronavirus
picornavirus
adenovirus
herp
virus
cytomegaloviru
cmv
epsteinbarr
viru
ebv
collier
oxford
although
rti
gener
selflimit
predominantli
viral
caus
patient
visit
healthcar
profession
often
expect
antibiot
perceiv
expect
antibiot
receiv
inappropri
antibiot
treatment
van
der
velden
et
al
europ
onequart
took
antibiot
last
year
provid
symptom
relief
remain
much
consum
confus
effect
antibiot
european
fals
believ
antibiot
kill
virus
believ
effect
cold
flu
european
commiss
physician
respond
sore
throat
patient
demand
actual
perceiv
prescrib
antibiot
approxim
case
barnett
linder
gulliford
et
al
sore
throat
adult
caus
bacteri
infect
shulman
et
al
unnecessari
use
antibiot
drive
develop
antibiot
resist
goossen
et
al
increasingli
seriou
threat
global
public
health
therefor
need
encourag
patient
rti
tri
altern
treatment
antibiot
reserv
patient
seriou
ill
increas
risk
complic
ideal
treatment
would
provid
symptomat
relief
patient
seek
well
treat
caus
local
deliv
format
lozeng
spray
use
enabl
activ
ingredi
reach
site
infect
directli
local
deliveri
mean
side
effect
lower
compar
system
act
treatment
farrer
lozeng
contain
antisept
local
anaesthet
amylmetacresol
amc
alcohol
dcba
hexylresorcinol
develop
treat
symptom
sore
throat
buchholz
et
al
foadi
et
al
mcnalli
et
al
mcnalli
et
al
wade
et
al
lozeng
demonstr
statist
signific
reduct
sore
throat
symptom
placebocontrol
clinic
trial
mcnalli
et
al
mcnalli
et
al
wade
et
al
amcdcba
lozeng
demonstr
antibacteri
effect
vivo
richard
et
al
vitro
richard
xing
amcdcba
lozeng
also
shown
virucid
effect
vitro
three
envelop
virus
rsv
influenza
viru
sever
acut
respiratori
syndrom
coronaviru
sarscov
oxford
et
al
studi
investig
vitro
virucid
activ
amc
dcba
alon
lozeng
two
envelop
virus
caus
sore
throat
respiratori
ill
piv
type
cmv
bisno
also
assess
vitro
virucid
activ
hexylresorcinol
alon
lozeng
knowledg
first
studi
examin
virucid
effect
throat
lozeng
virus
american
societi
test
materi
astm
intern
standard
method
standard
test
method
assess
activ
microbicid
virus
suspens
follow
challeng
virus
strain
atcc
cmv
strain
actt
obtain
american
type
cultur
collect
atcc
propag
vero
cell
atcc
cmv
cell
atcc
test
substanc
honey
lemon
amcdcba
lozeng
cherri
menthol
hexylresorcinol
lozeng
placebo
lozeng
amcdcba
free
activ
substanc
hexylresorcinol
free
activ
substanc
tabl
posit
control
sodium
hypochlorit
neg
control
dilut
medium
also
test
ml
aliquot
test
substanc
tabl
transfer
ml
conic
tube
ml
viru
stock
titr
tcid
ml
tcid
ml
cmv
ad
mix
immedi
vortex
ambient
room
temperatur
differ
contact
time
min
use
test
tabl
upon
complet
contact
time
reaction
mixtur
immedi
mix
vortex
equal
volum
neutral
rpmi
medium
newborn
calf
serum
hepe
nahco
amcdcba
experi
mem
hexylresorcinol
experi
mem
fetal
bovin
serum
hepe
nahco
amcdcba
cmv
experi
quench
sampl
serial
dilut
dilut
medium
serial
dilut
inocul
onto
host
cell
plate
ml
inoculum
per
well
n
per
dilut
inocul
plate
incub
co
day
amcdcba
experi
day
hexylresorcinol
experi
day
amc
dcba
cmv
experi
incub
period
titr
infecti
viru
determin
tcid
assay
use
spearmankarb
formula
result
neg
control
use
input
viral
load
compar
test
substanc
evalu
viral
reduct
test
substanc
experi
test
substanc
control
contact
time
run
triplic
mean
reduct
viral
titr
compar
test
substanc
placebo
lozeng
use
twosid
student
ttest
addit
control
test
also
conduct
assess
effect
neutral
cytotox
test
substanc
ml
aliquot
test
substanc
lozeng
combin
free
activ
substanc
mix
ml
dilut
medium
incub
ambient
room
temperatur
contact
time
equal
volum
neutral
ad
follow
serial
dilut
reaction
mixtur
dilut
medium
low
titr
viru
stock
contain
approxim
unit
viru
ad
ml
dilut
incub
ambient
room
temperatur
least
min
inocul
onto
host
cell
assess
presenc
infecti
viru
end
incub
period
evalu
cytotox
amc
amylmetacresol
cmv
cytomegaloviru
dcba
alcohol
mem
minimum
essenti
medium
parainfluenza
viru
type
g
sodium
bicarbon
g
sodium
chlorid
g
potassium
carbon
ad
ml
steril
deioniz
water
g
bovin
serum
albumin
ad
solut
ph
adjust
steril
deioniz
water
ad
reach
total
volum
ml
condit
host
cell
record
end
incub
period
viabil
host
cell
steril
cell
cultur
medium
test
inocul
control
cell
medium
incub
period
studi
titr
viru
stock
confirm
inocul
viru
stock
onto
host
cell
amcdcba
lozeng
exhibit
log
mean
log
reduct
viral
titr
min
log
mean
log
reduct
min
log
mean
log
reduct
min
fig
placebo
lozeng
exhibit
log
mean
log
reduct
min
log
mean
log
reduct
min
fig
amcdcba
free
activ
substanc
exhibit
log
mean
log
reduct
min
log
mean
log
reduct
min
fig
posit
control
exhibit
complet
inactiv
viru
within
min
fig
neg
control
exhibit
neg
effect
titr
viru
cell
viabil
data
shown
neither
amc
dcba
lozeng
amcdcba
free
activ
substanc
exhibit
direct
cell
cytotox
within
assay
data
shown
hexylresorcinol
lozeng
exhibit
log
mean
log
reduct
viral
titr
min
log
reduct
min
fig
placebo
lozeng
exhibit
log
mean
log
reduct
min
log
mean
log
reduct
min
fig
hexylresorcinol
free
activ
substanc
exhibit
log
reduct
min
fig
effect
posit
control
similar
hexylresorcinol
lozeng
hexylresorcinol
free
activ
substanc
fig
neg
control
exhibit
neg
effect
titr
viru
cell
viabil
data
shown
neither
hexylresorcinol
lozeng
hexylresorcinol
free
activ
substanc
exhibit
direct
cell
cytotox
within
assay
data
shown
amcdcba
lozeng
amcdcba
free
activ
substanc
well
posit
control
exhibit
log
reduct
viral
titr
timepoint
assess
fig
placebo
lozeng
exhibit
log
mean
log
reduct
min
log
mean
log
reduct
min
fig
neg
control
exhibit
neg
effect
titr
viru
cell
viabil
data
shown
neither
amc
dcba
lozeng
amcdcba
free
activ
substanc
exhibit
direct
cell
cytotox
within
assay
data
shown
studi
help
elucid
action
longstand
activ
ingredi
use
relief
sore
throat
show
amcdcba
hexylresorcinol
exhibit
virucid
activ
hexylresorcinol
amcdcba
cmv
vitro
four
subtyp
piv
caus
rti
although
less
known
henrickson
preval
season
piv
report
vari
studi
china
children
adult
rti
posit
piv
posit
season
peak
occur
april
juli
septemb
novemb
liu
et
al
studi
brazil
children
adult
influenzalik
ill
posit
preval
peak
second
half
year
freita
contrast
usa
season
peak
occur
spring
sometim
second
smaller
peak
autumn
fri
et
al
piv
caus
symptom
sore
throat
bisno
studi
china
patient
parainfluenza
viru
infect
symptom
pharyng
discomfort
liu
et
al
cmv
member
herp
viru
famili
infect
establish
latenc
approxim
global
popul
emeri
although
primari
cmv
infect
healthi
adult
usual
asymptomat
associ
mild
mononucleosislik
syndrom
cmv
caus
sever
lifethreaten
diseas
mortal
neonat
immunocompromis
adult
lancini
et
al
cmv
also
caus
sore
throat
bisno
studi
hospit
nonimmunocompromis
adult
confirm
presum
cmv
pharyng
bonnet
et
al
studi
activ
lozeng
free
activ
substanc
amcdcba
hexylresorcinol
exhibit
virucid
activ
within
min
minim
virucid
effect
beyond
min
greater
virucid
effect
observ
amcdcba
free
activ
substanc
amcdcba
lozeng
wherea
hexylresorcinol
free
activ
substanc
similar
effect
hexylresorcinol
lozeng
possibl
reason
includ
bind
amc
andor
dcba
excipi
amcdcba
lozeng
andor
interfer
possibl
protect
effect
excipi
lozeng
sore
throat
treatment
hexylresorcinol
routin
use
higher
dose
either
amc
dcba
may
also
factor
differ
virucid
effect
amcdcba
free
activ
substanc
amcdcba
lozeng
seen
cmv
suggest
mechan
virucid
action
amcdcba
lozeng
differ
two
virus
also
placebo
lozeng
amcdcba
hexylresorcinol
experi
appear
exert
virucid
activ
potenti
due
presenc
tartar
acid
placebo
lozeng
amcdcba
experi
osmot
pressur
chang
sticki
induc
sugar
placebo
lozeng
amc
dcba
hexylresorcinol
experi
oxford
et
al
due
action
excipi
eg
menthol
placebo
lozeng
hexylresorcinol
experi
studi
add
previou
observ
vitro
virucid
activ
amcdcba
lozeng
rsv
influenza
viru
sarscov
oxford
colleagu
data
suggest
amcdcba
hexylresorcinol
lozeng
potenti
inactiv
free
viru
infect
cycl
although
limit
studi
observ
vitro
effect
may
occur
vivo
phenol
amc
hexylresorcinol
alcohol
dcba
thought
disrupt
lipid
membran
alcohol
also
caus
rapid
denatur
protein
mcdonnel
russel
virucid
activ
substanc
like
due
effect
viral
lipid
membran
proteinlipid
interact
oxford
et
al
consist
theori
amcdcba
lozeng
thu
far
shown
exert
virucid
activ
envelop
virus
yet
nonenvelop
virus
oxford
et
al
find
studi
well
previou
research
oxford
et
al
suggest
amcdcba
lozeng
hexylresorcinol
lozeng
potenti
local
antivir
effect
patient
sore
throat
due
viral
rti
addit
lozeng
demonstr
efficaci
sore
throat
symptom
clinic
trial
mcnalli
et
al
mcnalli
et
al
wade
et
al
taken
togeth
data
support
use
lozeng
firstlin
treatment
sore
throat
caus
viral
rti
investig
mechan
action
clinic
effect
amcdcba
hexylresorcinol
control
rti
warrant
use
product
contain
activ
ingredi
reliev
symptom
also
help
treat
infecti
caus
rti
help
curb
patient
demand
antibiot
satisfi
need
treatment
infect
henc
reduc
burden
antibiot
resist
studi
fund
reckitt
benckis
healthcar
ltd
author
employe
reckitt
benckis
healthcar
ltd
involv
studi
design
analysi
interpret
data
took
decis
submit
articl
public
medic
write
assist
articl
fund
reckitt
benckis
healthcar
ltd
adrian
shephard
stela
zybeshari
employe
reckitt
benckis
healthcar
ltd
